Manufacturers interfering with access to 340B drugs prohibition extension

Minnesota Senate Bill 2959, introduced on March 24, 2025, aimed to extend a prohibition on drug manufacturers interfering with access to 340B drugs. The bill sought to repeal the expiration clause in Minnesota Statutes 2024, section 62J.96, subdivision 3, which was set to end the prohibition on July 1, 2027. By removing this expiration, the bill intended to make the prohibition indefinite, ensuring continuous access to discounted medications for healthcare providers serving low-income communities. ([revisor.mn.gov](https://www.revisor.mn.gov/bills/text.php?number=SF2959&session_number=0&session_year=2025&version=0&utm_source=openai))

While specific media coverage of Minnesota Senate Bill 2959 is limited, the bill's objectives align with broader national discussions on the 340B drug discount program. The program has been under scrutiny, with debates focusing on its effectiveness and the balance between pharmaceutical companies and healthcare providers. Extending the prohibition on interference with access to 340B drugs would likely be viewed positively by healthcare providers and patient advocacy groups, as it would ensure continued access to affordable medications for underserved populations. ([axios.com](https://www.axios.com/2023/08/11/340b-federal-drug-discount-scrutiny?utm_source=openai))

Specific negative media coverage of Minnesota Senate Bill 2959 is not readily available. However, the 340B program has faced criticism from pharmaceutical companies, which argue that some healthcare providers misuse the program to increase profits rather than aid vulnerable patients. If similar concerns were raised in Minnesota, the bill's extension of the prohibition might be viewed unfavorably by those advocating for stricter eligibility requirements and more controls on 340B pharmacy operations. ([axios.com](https://www.axios.com/2023/08/11/340b-federal-drug-discount-scrutiny?utm_source=openai))